Cargando…

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer

To curate the signature genes of cytotoxic lymphocytes (CLs) and explore the heterogeneity based on the CL-related (CLR) gene signature, we analyzed the gene expression of 592 patients with histologically diagnosed triple-negative breast cancer. Based on the 13-gene panel, CLR signatures were curate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yiqun, Wang, Jiayu, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054905/ https://www.ncbi.nlm.nih.gov/pubmed/36983639 http://dx.doi.org/10.3390/jpm13030457

Ejemplares similares

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2021)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis
por: Han, Yiqun, et al.
Publicado: (2020)

There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population
por: Ma, Fei, et al.
Publicado: (2013)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis
por: Han, Yiqun, et al.
Publicado: (2021)

Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
por: Ma, Fei, et al.
Publicado: (2017)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis
por: Han, Yiqun, et al.
Publicado: (2021)

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
por: Xu, Hangcheng, et al.
Publicado: (2022)

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
por: Han, Yiqun, et al.
Publicado: (2022)

Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Zhijun, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis
por: Xu, Hangcheng, et al.
Publicado: (2022)

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis
por: Wang, Jiani, et al.
Publicado: (2022)

A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer
por: Ma, Fei, et al.
Publicado: (2014)

Autophagy-related prognostic signature for survival prediction of triple negative breast cancer
por: Yang, Qiong, et al.
Publicado: (2022)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner, Jessica, et al.
Publicado: (2015)

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer
por: Zhu, Anjie, et al.
Publicado: (2016)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries
por: Zhu, Wenjie, et al.
Publicado: (2015)

Identification of ubiquitination-related gene classification and a novel ubiquitination-related gene signature for patients with triple-negative breast cancer
por: Zhao, Kankan, et al.
Publicado: (2023)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Su, Peng, et al.
Publicado: (2021)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
por: Sha, Shengnan, et al.
Publicado: (2022)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
por: Sun, Xiaorui, et al.
Publicado: (2022)

Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018)

A clinically relevant gene signature in triple negative and basal-like breast cancer
por: Rody, Achim, et al.
Publicado: (2011)

Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature
por: Qin, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_emddi7e945brhijdvk48k005bh